Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/05/2022|
|Rapid review completed||03/06/2022|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that dapagliflozin be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.